Is the treat-retreat strategy a viable option for atopic dermatitis patients undergoing Janus kinase inhibitor treatment? A report on two successful cases with upadacitinib

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e54-e55. doi: 10.1111/jdv.19430. Epub 2023 Sep 5.

Author

Ignasi Figueras-Nart¹

Affiliation

¹ Dermatology, Hospital Universitari de Bellvitge, Univeristy of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

PMID: 37594471
DOI: 10.1111/jdv.19430

No abstract available

Publication types

Letter

MeSH terms

Dermatitis, Atopic* / drug therapy
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Janus Kinase Inhibitors* / therapeutic use
Treatment Outcome

Substances

upadacitinib
Janus Kinase Inhibitors
Heterocyclic Compounds, 3-Ring